Plus Therapeutics Announces New Category III CPT Code for REYOBIQ Convection-Enhanced Delivery

Reuters02-25 20:30

Plus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces New Category III CPT Code for REYOBIQ Convection-Enhanced Delivery

Plus Therapeutics Inc. said the American Medical Association’s CPT Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery used to administer REYOBIQ for recurrent glioblastoma and pediatric brain cancer. The approved code is X566T, covering stereotactic placement of brain infusion catheter(s) for delivery of therapeutic agents, including computerized stereotactic planning and burr hole(s). The company said the code will be published July 1, 2026, and will become effective for reporting on Jan. 1, 2027. Plus Therapeutics also said it expects to complete enrollment in its Phase 2 recurrent glioblastoma trial in 2026, followed by an end-of-Phase 2 meeting, and continues to expect first patient enrollment in its Phase 1 pediatric brain cancer trial in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602250730PRIMZONEFULLFEED9660646) on February 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614084530?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614084530","market":"nz","top_or_hot":-1,"title":"Plus Therapeutics Announces New Category III CPT Code for REYOBIQ Convection-Enhanced Delivery","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Plus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces New Category III CPT Code for REYOBIQ Convection-Enhanced Delivery\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Plus Therapeutics Inc. said the American Medical Association’s CPT Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery used to administer REYOBIQ for recurrent glioblastoma and pediatric brain cancer. The approved code is X566T, covering stereotactic placement of brain infusion catheter(s) for delivery of therapeutic agents, including computerized stereotactic planning and burr hole(s). The company said the code will be published July 1, 2026, and will become effective for reporting on Jan. 1, 2027. Plus Therapeutics also said it expects to complete enrollment in its Phase 2 recurrent glioblastoma trial in 2026, followed by an end-of-Phase 2 meeting, and continues to expect first patient enrollment in its Phase 1 pediatric brain cancer trial in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602250730PRIMZONEFULLFEED9660646) on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Plus Therapeutics Announces New Category III CPT Code for REYOBIQ Convection-Enhanced Delivery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPlus Therapeutics Announces New Category III CPT Code for REYOBIQ Convection-Enhanced Delivery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-25 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Plus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces New Category III CPT Code for REYOBIQ Convection-Enhanced Delivery\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Plus Therapeutics Inc. said the American Medical Association’s CPT Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery used to administer REYOBIQ for recurrent glioblastoma and pediatric brain cancer. The approved code is X566T, covering stereotactic placement of brain infusion catheter(s) for delivery of therapeutic agents, including computerized stereotactic planning and burr hole(s). The company said the code will be published July 1, 2026, and will become effective for reporting on Jan. 1, 2027. Plus Therapeutics also said it expects to complete enrollment in its Phase 2 recurrent glioblastoma trial in 2026, followed by an end-of-Phase 2 meeting, and continues to expect first patient enrollment in its Phase 1 pediatric brain cancer trial in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602250730PRIMZONEFULLFEED9660646) on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDLb7S3X6:1","article_id":"2614084530","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614084530","pubTimestamp":1772022622,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Plus Therapeutics Inc. said the American Medical Association’s CPT Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery used to administer REYOBIQ for recurrent glioblastoma and pediatric brain cancer. The approved code is X566T, covering stereotactic placement of brain infusion catheter for delivery of therapeutic agents, including computerized stereotactic planning and burr hole. The company said the code will be published July 1, 2026, and will become effective for reporting on Jan. 1, 2027. Plus Therapeutics also said it expects to complete enrollment in its Phase 2 recurrent glioblastoma trial in 2026, followed by an end-of-Phase 2 meeting, and continues to expect first patient enrollment in its Phase 1 pediatric brain cancer trial in 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","PSTV":"Plus Therapeutics, Inc.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD"},"translate_title":"Plus Therapeutics宣布REYOBIQ对流增强输送的新III类CPT代码","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSTV":0.9,"NDAQ":0.9},"content_text":"Plus Therapeutics Announces New Category III CPT Code for REYOBIQ Convection-Enhanced Delivery\n    \n\n        Plus Therapeutics Inc. said the American Medical Association’s CPT Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery used to administer REYOBIQ for recurrent glioblastoma and pediatric brain cancer. The approved code is X566T, covering stereotactic placement of brain infusion catheter(s) for delivery of therapeutic agents, including computerized stereotactic planning and burr hole(s). The company said the code will be published July 1, 2026, and will become effective for reporting on Jan. 1, 2027. Plus Therapeutics also said it expects to complete enrollment in its Phase 2 recurrent glioblastoma trial in 2026, followed by an end-of-Phase 2 meeting, and continues to expect first patient enrollment in its Phase 1 pediatric brain cancer trial in 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602250730PRIMZONEFULLFEED9660646) on February 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614084530","isCrawlerRequest":true}